TFF2 and neuropathy: The main findings of this report are that (1) Systemic rhEPO treatment prevent RTX-induced neuropathy by its neuroprotective properties (2) A functional SFN induced by RTX with a CGRP and SP depletion, promotes skin PU development, after a long ischemic pressure application (3) PU formation is increased independently by CGRP antagonist (CGRP8-37) and SP antagonist (SR140333) (4) Neuroprotective effect of rhEPO restores skin capacity to protect against ischemic pressure in RTX-induced neuropathy model.